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The Role of RhoG in migration and invasion of glioblastoma cells 
Amani Ezzeddine  
 
ABSTRACT 
 
Metastasis is the movement of a tumor from its original site to a secondary site. The 
ability of cancer cells to metastasize depends on their motility and actin-rich 
membrane protrusions. These protrusions and motility are regulated by Rho 
GTPases. Rho GTPases are 20KD proteins that act as molecular switches. RhoG, our 
protein of interest, belongs to this family and is known to almost have the same 
sequence and function as Rac1. Literature states that RhoG is involved in cell 
motility, actin cytoskeleton, and many signaling mechanisms. Previous studies 
showed that RhoG plays a role in the invasive behavior of glioblastoma cells. Also, 
RhoG was found to be overexpressed in many tumor tissues. In this paper, we 
studied the role of RhoG in migration and invasion of glioblastoma cells. To study 
the effect of RhoG on motility, cells were transfected either with si-Luciferase or 
with si-RhoG (oligo 5 and 8). The results show that upon RhoG knockdown, the 
motility of Snb-19 cells decreased. This characteristic was further elucidated through 
immunostaining. Here, the cells were knocked down using si-RhoG and stimulated 
with PMA. Our results showed that the ruffles are RhoG independent and that the 
inhibition of RhoG forms stress fibers. Invasion assay also showed a decrease in cell 
invasion when RhoG was knocked down. Similarly, the adhesion assay revealed a 
decrease in adhesion of Snb-19 cells upon RhoG knockdown. Finally, a pull-down 
assay was done for the Rho family of GTPases which showed that RhoG 
downregulates RhoA and Rac1 activation levels. Indeed, RhoG like other previously 
tested Rho GTPases is involved in cancer metastasis. It does so by positively 
regulating cell motility and invasion. Further studies need to be done to elucidate the 
exact function of RhoG on such characteristics.  
Keywords: Metastasis, Rho GTPases, Cell Motility, Invasion, Adhesion 
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Chapter 1 
Literature Review 
 
 
1.1. Cancer  
 
1.1.1. Background 
Cancer is the out of control growth of normal cells causing a tumor which can 
spread to different parts of the body and cause death. Spreading to other organs and 
invading adjacent parts is called metastasis. Increasing cancer survival rates include 
early detection and effective treatment (World Health Organization, 2013). There are 
two types of tumors: benign or malignant tumors. Benign tumors do not spread or 
invade other organs and are not cancerous. However malignant tumors can spread to 
other organs and grow faster than benign tumors. Once the tumor breaks the 
basement membrane it becomes malignant (National Cancer institute, 2013). 
 
Figure 1: Development of mutations. When mutations accumulate a tumor will 
form and more mutations will convert it to malignant tumor and even to metastatic 
tumor. Source: (Jay D. Hunt, LSU Health Sciences Center) 
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The first step in the growth of cancer is the development of genetic 
mutations. However; in order for the mutated cell to survive it must compete with 
other normal cells by dividing faster and becoming more adhesive (Szabo & Merks, 
2013). The growth of a tumor depends on the modifications of the cell’s properties. 
These modifications are called the “hallmarks of cancer” which includes: evading 
growth suppressors, activating invasion and metastasis, enabling replicative 
immortality, inducing angiogenesis, resisting cell death, and sustaining proliferative 
signaling (Hanahan & Weinberg, 2011). 
 
 
 
 
Figure 2: The Hallmarks of Cancer. This figure represents the six hallmark 
capabilities of cancer. Source: (Hanahan and Weinberg, 2011) 
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1.1.2. Brain cancer 
Gliomas are brain cancers that arise from glial cells (Ferlug et al., 2014). 
Astrocytes, oligodendrocytes, and microglial cells are 3 types of glial cells that have 
3 different functions (Biasoli et al., 2014). The largest type of glial cells is astrocytes 
which transports nutrients. Oligodendrocytes are responsible for providing myelin to 
neurons however microglial cells phagocytize dead neurons and microbes (Yang et 
al., 2013). 
Gliomas can be classified according to the aggressiveness of the cancer cells 
and the type of glial cells. Grades I and II astrocytoma are non-malignant tumors 
unlike grades III and IV (Ostrom, et al., 2014). Grade III astrocytoma are anaplastic 
astrocytoma (AAs) however Grade IV astrocytoma are the most aggressive and 
malignant tumors also known as glioblastoma (GB) (Thomas at al., 2014). Usually 
gliomas do not metastasize outside the brain but they can be invasive within the 
white-matter of the cerebrum and corpus callosum (Shannon et al., 2013). 
Glioblastoma also known as glioblastoma multiforme (GBM) spreads quickly 
and invades other parts of the brain (Thomas at al., 2014). Glioblastoma form in the 
cerebral white matter and may expand to the ventricular wall (Thomas at al., 2014). 
There are 2 types of glioblastoma tumors: primary glioblastoma with a new history 
of the disease or secondary glioblastoma that have previous history of lower grade 
astrocytoma (Shannon et al., 2013). They are highly malignant tumors since 
glioblastoma is characterized by an increase of abnormal growth of blood vessels 
around the tumor (Parsons et al., 2008). They may metastasize outside of the central 
nervous system (CNS) and may be highly invasive within the CNS (Shannon et al., 
2013). 
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1.1.3. Tumor diagnosis and treatment 
Even though there are many advances and developments in treating most 
types of cancer, the survival rate of patients with glioblastoma is one to two years 
with less than 3% surviving for 5 years (Johnson & O’Neill, 2012). Treatment of 
glioblastoma is still ineffective despite all the approaches including radiation, 
chemotherapy, and surgery (Stupp et al., 2005). The tumor cells are resistant and 
many drugs are unable to cross the blood brain barrier to act on the tumor (Stupp et 
al., 2005). The invasiveness of tumor cells into normal brain tissue leads to a diffuse 
tumor with no clear edges. Also glioblastoma with the stem-like-self-renewal 
property has been shown to be resistant to various therapies (Paw et al., 2015).   
 
1.2. The family of Rho GTPases 
The Rho family belongs to the Ras super family which are (21-25 kDa) small 
proteins. Rho, Rac, Cdc42, RhoD, RhoF, RhoH, and Rnd are members of the Rho 
family (Fortin et al., 2013). Rho is responsible for focal adhesion formation whereas 
Rac is responsible for membrane ruffling and Cdc42 for folipodium formation (Parri 
& Chiarugi., 2010).  All Rho GTPases are molecular switches that play a role in cell 
motility, cell polarity, actin polymerization, vesicular trafficking, and cell invasion. 
1.2.1. Structure of Rho GTPases 
All members of the Rho GTPases family have a constant Rho domain and a 
conserved sequence of amino acids at their C-terminal and N-terminal. Post-
translational modifications occurs at the CAAX box at their C-terminal (Magee et al., 
1992). At their N-terminal, Rho GTPases bind to GTP or GDP (Johnson, 1999). 
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Switch I is a Rho binding domain which activates many downstream effectors 
(Marshall, 1993) (Figure 5). 
 
 
Figure 3: Primary structure of Rho GTPases. The Rho domain in Rho GTPases. 
Source: (Gad & Aspenstrom, 2010) 
 
1.2.2. Regulation of Rho GTPases  
Rho GTPases switches between two states: an active state where they bind to 
GTP or an inactive state where they bind to GDP (Kwiatkowska et al., 2012). In the 
active GTP-bound state the GTPase can communicate with downstream effectors. 
Guanine nucleotide exchange factors (GEFs), GTPase-activating proteins (GAPs), 
and guanine nucleotide dissociation inhibitors (GDIs) regulates the switching 
between the inactive and active state (Nobes & Hall, 1995).  
1.2.2.1. GEFs: 
The dissociation of GDP from Rho GTPases is a very slow reaction and the 
rate limiting step in Rho GTPase activation. GEFs increase the rate of GDP 
dissociation. GEFs interact with phospholipids at the plasma membrane thus altering 
GDP-GTP exchange (Schmidt & Hall, 2002). GEFs have major domains such as Src 
homology 3 (SH3), pleckstrin homology domain (PH), and Dbl homology domain 
(DH) (Grise et al., 2009). In fact, GEFs activate Rho GTPases. 
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1.2.2.2. GDIs: 
GDIs prevent the dissociation of GDP of inactive Rho GTPases (Gracia-Mata 
et al., 2011). GDIs help Rho GTPases in cycling between the cytoplasm and cell 
membrane (Grise et al., 2009). In the cytosol, GDIs sequester Rho GTPases in their 
inactive form by hiding the binding domain of GTPases thus they are away from 
their activation site which is the cell membrane (Gracia-Mata et al., 2011). 
1.2.2.3. GAPs: 
GAPs activate the intrinsic GTPase activity by hydrolyzing GTP into GDP, 
hence switching Rho GTPases to their inactive form (Moon & Zheng, 2003). 
Therefore GAPs negatively regulate Rho GTPases. 
 
 
 
 
Figure 4: Regulation of Rho GTPases. This illustration represents the regulation of 
Rho GTPases between the active and inactive states. Source: (Ensign et al., 2013) 
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1.2.3. Rho GTPases subfamilies  
RhoA 
RhoA plays a role in tumor survival and cell proliferation and it is important 
for migration (Vega & Ridley, 2008). Inhibiting RhoA promotes the increase in cell 
migration (Tran et al., 2006). Inhibiting Ras in astrocytoma increases the activation 
of RhoA and causes stress fiber formation and cell immobility (Goldberg & Kloog, 
2006). Inhibiting ROCK, which is an effector of RhoA, promotes invasion by 
activating Rac1 and also increases membrane ruffling and inhibits actin stress fibers 
(Ramis et al., 2012).  
 
RhoC: 
RhoC is restricted to cancer metastasis (Hakem et al., 2005). Studies showed 
that increased expression of RhoC was shown in invasion and metastasis (Ma et al., 
2007). Knock down of RhoC in vitro confirms that RhoC is essential for invasion 
and metastasis (Bellovin et al., 2006). Also knock out of RhoC in mice models 
showed that RhoC is important for tumor initiation (Hakem et al., 2005). However it 
is not clear yet how RhoC functions to increase metastasis and invasion or why it 
differs from RhoA (Vega & Ridley, 2008). Some papers indicate that RhoA and 
RhoC have a common downstream effector (ROCK) which is important in cancer 
cell extravasation (Miles et al., 2008). In breast cancer, RhoC triggers the formation 
of angiogenic factors which helps the cancer cells to enter the blood vessels and thus 
metastasize (Merajver & Usmani, 2005).  
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RhoG: 
RhoG is homologous with Rac1 and Cdc42, however it is unable to bind to 
the CRIB domain (Wennerberg et al., 2002). It is involved in cell motility, regulating 
actin cytoskeleton, and gene transcription (Gauthier-Rouvière et al., 1998). Earlier 
studies showed that the expression of activated Rac1 and Cdc42 with RhoG causes 
an increase in the activity than that seen with only Cdc42 and Rac (Roux et al., 
1997). On the other hand, another study showed that RhoG causes a downstream 
activation of Cdc42 and Rac1 (Gauthier-Rouvière et al., 1998). For example, RhoG-
induced neurite growth was inhibited in PC12 cells when dominant-negative mutants 
of Rac1 and Cdc42 were induced (Katoh et al., 2000). Also Cdc42 and Rac1 
activation increases when the expression of RhoG increases (Katoh et al., 2000). 
Therefore, RhoG signaling pathway is connected to Cdc42 and Rac1. However, the 
mode of activation of Cdc42 and Rac1 by RhoG is not well defined. Till now little is 
known about the upstream signals and effectors of RhoG (Wennerberg et al., 2002). 
Extracellular stimuli activates the Dbl-family of GEFs such as Vav2, Vav3, and Trio 
which in turn activates RhoG (Schuebel et al., 1998). Also GEFs activate Rac so 
RhoG and Rac may be activated at the same time instead of sequentially (Movilla & 
Bustelo, 1999). The two-hybrid binding analyses shows that RhoG is not interacting 
with WASP or Pak1 which are binding partners of Cdc42 and Rac1 thus RhoG 
mediates Rac1 and Cdc42 pathways (Gauthier-Rouvière et al., 1998). 
 
Rac: 
Rac1 is overexpressed or mutated in different cancer tumors (Vega & Ridley, 
2008). The increased expression of Rac1 in cancers is due to its stimulation of cell 
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survival through NFκB (Singh et al., 2004). Rac1 in its mutated form does not bind 
Rho GDI so it is always present in the GTP active state (Vega & Ridley, 2008). Rac1 
triggers the expression of cyclin D1 thus leading to cancer cell proliferation (Jaffe & 
Hall, 2005). Also Rac1 promotes tumor cell invasion by inhibiting adhesion 
structures thus helping the cell to migrate more (Engers et al., 2001). Rac1 is 
important for lamellipodial protrusions during mesenchymal and amoeboid migration 
(Friedl & Wolf, 2003). 
In astrocytoma, Rac1 is over activated which leads to the invasive behavior of 
glioma cells (Salhia et al., 2008). Rac3, which is similar to Rac1, also plays a role in 
the invasion of glioma cells because knocking down Rac3 inhibits cell invasion 
(Chan et al., 2005). Rac1-activating mutations were found in melanoma tissue 
however these mutations were not found in glioblastoma and astrocytoma 
(Krauthammer et al., 2012). 
Rac1 plays a role in the formation of invadopodia (Gimona et al., 2008). 
Invadopodia are protrusions of the plasma membrane that promote the breakdown of 
the extracellular matrix which leads to invasion and metastasis in glioma cells (Chan 
et al., 2005). Rac1 depletion has been reported to decrease invadopodia formation 
thus inhibiting glioma cell invasion. Rac1 is also activated downstream of many 
receptors that induces the malignancy of glioma cells (Fortin et al., 2013). For 
example, the PDGFRα which is overexpressed in many gliomas induced an increase 
in Rac1-GTP activity which leads to glioma cell invasion (Feng et al., 2011). Also 
Rac1 activation has been reported downstream of other Rho GTPases like IQ-domain 
GTPase-activating protein 1 (IQGAP1)-dependent ADP-ribosylation factor 6 (ARF6) 
signaling (Hu et al., 2009). 
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Cdc42: 
Cdc42 regulates cell migration and cell polarity by functioning upstream of 
Rac1 (Katoh et al., 2006). Cdc42 is also activated downstream of PDGFRα 
association with Dynamin 2 (Dyn2) and SHP-2 non-receptor protein tyrosine 
phosphatase which leads to glioma cell migration (Feng et al., 2012). Knocking 
down ARHGAP21, which is a Cdc42 specific GAP, increases Cdc42 activity and the 
rate of cell migration (Bigarella et al., 2009). Also it is required for directional 
sensing and morphogenesis (Cau & Hall, 2005). Knocking down Cdc42 causes 
chromosome misalignment during mitosis thus Cdc42 regulates chromosome 
segregation (Vega & Ridley, 2008). 
 
1.3. Rho GTPase signaling pathways 
Growth factors bind to plasma membrane receptors which regulate Rho 
GTPases and activate downstream pathways (Sahai & Marshall, 2002). These 
pathways include cell adhesion, cytoskeleton reorganization, cell polarity, and others 
(Sahai & Marshall, 2002).  
1.3.1. Upstream signaling 
1.3.1.1. PI3K signaling 
One main upstream signaling of Rho GTPases is the PI3K. Phosphoinositide 
3-kinases (PI3Ks) are involved in cell proliferation, vesicle trafficking, and cell 
growth (Engelman et al., 2006). EGF and PDGF are growth factors that activate Rho 
GTPases through the PI3K pathway (Nobes et al., 1995). Studies showed that when 
PI3K is inhibited, members of the Rho GTPase family were inhibited too (Nobes et 
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al., 1995). This proves that Rho GTPases are downstream of PI3K pathway. GEFs 
have a PH domain which binds to phosphoinositides such as PIP3 which allows the 
interaction between the PH and DH domain of GEF (Macias et al., 1994). DH 
domain or RhoGEF domain is a region that induces the Rho family GTPases to 
displace GDP. PI3K phosphorylates PIP2 into PIP3 which allows PIP3 to bind to the 
PH domain (Schmidt & Hall, 2002). Vav and Son of sevenless (Sos) are important 
GEFs which binds to PIP3 through their PH domain thus weakening the interaction 
between PH and DH domains (López-Lago et al., 2000). In this way the inhibition 
exerted by the PH domain is removed. Despite the defined set of signaling pathways, 
the understanding of cell movement is complex because the cell motility in a tumor 
does not occur in a mesenchymal way and a well-defined leading cell edge; however 
it has an amoeboid fashion and depends on the environment around the cell 
(Machacek et al., 2009).  
1.3.2. Downstream signaling 
Rho, Rac, and Cdc42 are downstream effectors of the PI3K pathway 
(Ananthakrishnan & Ehrlicher, 2007). These Rho GTPases play an important role in 
stress fiber formation, actin polymerization, and cell cytoskeleton (Etienne-
Manneville & Hall, 2002). 
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Figure 5: Downstream effectors of Rho, Rac, and Cdc42. This illustration 
represents the downstream effectors of different Rho GTPases. Source: (Zhou & 
Snider, 2006) 
 
 
Rho is regulated by the PI3K signaling pathway. One of its effectors is 
ROCK which phosphorylates the myosin light chain (MLC) (Grise et al., 2009). This 
regulates the actin and myosin contractility (Grise et al., 2009). Rho can also activate 
mDia leading to stress fiber formation and actin polymerization (Alberts, 2001). 
PAK, WAVE, and N-WASP are downstream effectors of Rac and Cdc42 
(Keely et al., 1997). Pak is a serine/threonine activating kinase. These proteins have a 
binding domain for Rac and Cdc known as the CRIB domain (Burbelo et al., 1995). 
They also have a catalytic and a regulatory domain at their C-terminal and N-
terminal, respectively (Manser et al., 1994). These effector proteins are involved in 
restructuring the cytoskeleton such as actin polymerization and microtubule 
stabilization (Burbelo et al., 1995). 
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1.4. Role of Rho GTPases in glioblastoma 
 
Overexpression of Rho GTPases plays a role in glioblastoma formation (Zhai 
et al., 2006). Some members of the Rho GTPases family such as RhoG, Rac1, and 
Cdc42 mediates glioblastoma cell invasion (Shannon et al., 2013). Therefore they 
represent a therapeutic target against glioblastoma.  
Rac1 plays a role in the invasive behavior of glioblastoma since it is 
overexpressed in glioblastoma tumors (Salhia et al., 2008). Rac1 promotes the 
formation of lamellipodia which are cross linked networks that move the cell by 
polymerizing against the plasma membrane thus plasma membrane staining shows 
increased activity of Rac1 in glioblastoma (Tran et al., 2006). On the other hand, 
Rac3 which is similar in structure to Rac1, was also found to play a role in the 
invasive behavior of glioblastoma since knocking down Rac3 in glioblastoma cells 
inhibited the invasion of glioblastoma cells (Chan et al., 2005). 
Also Rac1 promotes the formation of invadopodia which are plasma 
membrane protrusions that degrade the extracellular matrix (Gimona et al., 2008). 
Invadopodia is important in cell invasion and metastasis of glioblastoma. Previous 
results showed that knocking down Rac1 led to a decrease in invadopodia formation 
and thus glioblastoma cell invasion (Chuang et al., 2004). 
On the other hand, immunohistochemical analysis revealed RhoG to be 
overexpressed in human glioblastoma tissues which shows that RhoG plays a critical 
role in the malignant behavior of glioblastoma (Kwiatkowska et al., 2012). In order 
to understand the mechanism of action of RhoG in glioblastoma, several experiments 
were done.  
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RhoG uses Rac1 dependent and Rac1 independent mechanisms to regulate 
glioblastoma cell invasion (Kwiatkowska et al., 2012). This was proved since RhoG 
and Rac1 are activated by HGF (hepatocyte growth factor) and Rac1 acts 
downstream of RhoG (Brockmann et al., 2003). When RhoG is knocked down, Rac1 
activation is inhibited partially which indicates that HGF can activate Rac1 in a 
RhoG independent mechanism (Kwiatkowska et al., 2012). However the effect of 
knocking down RhoG on glioblastoma cell invasion is the same as the effect of 
knocking down Rac1 (Kwiatkowska et al., 2012). This shows that RhoG regulates 
cell invasion of glioblastoma in a Rac1-dependent and Rac1-independent 
mechanisms.      
 
1.5. Actin Organization and Cell Mechanics 
Cell motility and cell division are cellular processes that depend on the 
assembly of actin to change their shape. Actin is a globular protein that forms 
different types of filaments. These filaments have a mechanical force to drive cell 
motility and changes in the cell shape (Blanchoin et al., 2014). 
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Figure 6: Actin architecture and mechanics in the moving cell. A schematic 
representation of the cell with the different actin architectures. Source: (Blanchoin et 
al., 2014). 
 
 
Once myosin and actin assemble with each other they lead to the contraction 
of the cell. Filopodia are found at the front of the cell and play a role in directional 
response. Lamellipodia are cross linked networks that move the cell by polymerizing 
against the cell membrane (Condeelis et al., 2001). Membrane ruffles arise at the 
leading edge of lamellipodia (Borm et al., 2005). They are densely packed actin 
filaments at the leading edge (Borm et al., 2005). However their mechanism of 
formation and structure is still unknown. The cortex covers the cell membrane and is 
important in maintaining the shape of the cell. The stress fibers are cross linked 
filaments that join the cytoskeleton to the extracellular matrix (Andrianantoandro & 
Pollard, 2006). 
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1.6. Cell motility 
Cell motility can be divided into 3 steps: direction of motion, protrusion, and 
adhesion formation (Lauffenburger & Horwitz, 1996). 
 
 
 
Figure 7: Rho GTPases in the cell motility cycle. A migratory cell in the cell 
motility cycle in response to a chemoattractant. Source: (Hanna & El-Sibai, 2013) 
 
Cell motility is important for cell invasion and metastasis in cancer, thus 
understanding cell motility as a therapeutic target can inhibit tumor growth 
(Lauffenburger & Horwitz, 1996). It is involved in several physiological events like 
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wound healing and tissue regeneration (Hanna & El-Sibai, 2013). Cell migration 
takes place as a response to a chemoattractant signal found around the cell (Hanna & 
El-Sibai, 2013). Once the cell detects the signal it starts moving in an amoeboid like 
manner with the direction of motion towards the chemoattractant in a process known 
as protrusion by polymerizing actin filaments (Bailly et al., 1998). Adhesion 
structures are formed to stabilize the actin-rich protrusions to the cell substratum 
(Ananthakrishnan & Ehrlicher, 2007). The cell moves forward by disassembling the 
adhesion structures at the rear ends, therefore the cell retracts its tail and moves 
towards the direction of motion (Hanna & El-Sibai, 2013).  
1.6.1. Direction of motion and protrusion 
Protrusion is the process by which the cell pulls its body forward thus the 
adhesion elements at the end of the cell are detached so the cell will retract its tail 
and moves forward towards the direction of motion (Ananthakrishnan & Ehrlicher, 
2007). Protrusions can be either filopodia or lamellipodia (Tang et al., 2007). 
Filopodia are regulated by cdc42 which determines the direction of motion (Nobes & 
Hall, 1995). They function as sensors for chemo attractants (Ridley, 2001). Filopodia 
form through the activation of N-WASP (Ridley, 2001). However lamellipodia at the 
leading edge are regulated by Rac and its downstream effectors such as Arp2/3 
which plays a role in actin nucleation (Van Troys et al., 2008). 
1.6.2. Adhesion formation 
When protrusions are formed they have to be stabilized by adhering to the 
ECM (DeMali & Burridge, 2003). The first step in adhesion is the formation of 
integrins at the leading edge of protrusions (Borm et al., 2005). These integrins 
activate small GTPases such as RhoA and Rac which stabilize the formation of 
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adhesions (DeMali et al., 2003). Rac activates PAK which leads to the formation of 
focal adhesion complexes and recruits cytockeletal and focal adhesion proteins 
(Borm et al., 2005). RhoA is responsible for dissolution of old adhesions so the tail 
can retracts and the cell moves forward (Johnson, 1999). 
 
1.7. Cell invasion 
Cell invasion is involved in the physiopathology of cancer diseases (Bozzuto 
et al., 2010). Cell invasion is a process that allows cells to enter the blood vessels and 
then metastasize into different organs (Bozzuto et al., 2010). During metastasis, the 
cells must first detach from the primary tumor site, degrade the basal lamina, migrate 
towards blood vessels, and finally proliferate at secondary site (Gertler & Condeelis, 
2011) (figure 8). 
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Figure 8: Process of invasion and metastasis. Cells invade through the basement 
membrane to form metastasis. Source: (Alberts et al., 2002) 
 
1.7.1. ECM degradation 
The first step in cell invasion is degrading the extracellular matrix (ECM) 
(Friedl & Wolf, 2003). The ECM is made up of glycoproteins, proteoglycans, and 
type IV collagen (Kim et al., 1993). These components must be degraded in order for 
the cancer cells to invade (Bozzuto et al., 2010). For that reason, cancer cells produce 
proteases such as matrix metalloproteinases (MMPs) (Stivarou & Patsavoudi, 2015). 
The most known MMPs are MMP-2 and MMP-9 (Stivarou & Patsavoudi, 2015). 
MMPs are produced in their inactive form and thus have to be activated by the help 
of plasmin (Galis & Khatri, 2002). However first the MMPs must escape 
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extracellular inhibitors like TIMPs (Egeblad & Werb, 2002). After degrading the 
ECM, cells will migrate to the blood and lymphatic vessels by a process known as 
angiogenesis (Egeblad & Werb, 2002). Then the cancer cells will escape from the 
blood vessels into surrounding tissues in a process known as extravasation (Galis & 
Khatri, 2002). Now the cells are able to proliferate in the secondary site (Galis & 
Khatri, 2002). Therefore, cancer cells will invade and metastasize and neoplastic 
tissues will form in secondary sites. 
1.7.2. Molecular mechanism of invasion 
Cancer cells must first form protrusions with the help of MMPs in order to 
invade the basal lamina in a process known as invadopodia (Bravo-Cordero., 2011). 
Invadopodia are enriched with actin filaments associated with matrix proteinases 
(Condeelis & Segal., 2003). Invadopodia induces many signaling pathways and 
proteins such as cofilin, Arp2/3, and N-WASP (Artym et al., 2006). Cofilin cut actin 
filaments producing free barbed ends and exposing the actin filaments (Artym et al., 
2006). Arp2/3 produces barbed ends by de novo nucleation (Olson & Sahai, 2009). 
N-WASP have a VCA domain which binds Arp2/3 (Olson & Sahai, 2009). In 
conclusion, the regulation of invadopodia are important for invasion and metastasis.  
 
 
 
 
 
 
 21 
 
1.8. Purpose of this study 
Members of the Rho GTPases were found play a role in many types of 
cancers. Therefore the purpose of this study is to study the role of RhoG in the 
invasive behavior of glioblastoma cells. Also we studied the role of RhoG on cell 
motility of glioblastoma cells. The goal of this study is to help find a future approach 
for targeting cancer. 
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Chapter 2 
Materials and Methods 
 
2.1. Cell culture  
The cells used in the present study were human adult glioblastoma cell lines 
SF268 and Snb-19. All cells were cultured in Dulbecco’s modified eagle medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS) and 100U of penicillin/ 
streptomycin at 37°C and 5% CO2 in a humidified chamber 
  
2.2. Antibodies and Reagents  
The following primary antibodies were used in this study: Mouse monoclonal 
antibody against RhoG was purchased from abcam (Abcam Inc., Cambridge, UK), rabbit 
polyclonal antibody against RhoG was purchased from santa cruz (Santa Cruz 
Biotechnology., California, US), rabbit polyclonal antibody against Actin was purchased 
from abcam (Abcam Inc., Cambridge, UK). Anti-rabbit, anti-mouse HRP-conjugated 
secondary antibodies were obtained from promega (Promega Co., Wisconsin). 
Fluorescent secondary antibodies (Alexa Fluor 488, 594) were obtained from Invitrogen. 
To visualize the actin cytoskeleton, cells were stained with Rhodamine-phalloidin 
(Invitrogen).  
2.3. Cell transfection with siRNA  
Flexi Tubes siRNA for Rho G oligo 5 and 8 were obtained from qiagen (Qiagen, 
USA). The cells were transfected with the siRNA at final concentration of 10 nM using 
Hiperfect (Qiagen, USA) as described by the manufacturer. Control cells were 
transfected with siRNA sequences targeting GL2 Luciferase (Qiagen, USA). After 72 
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hours, protein levels in total cell lysates were analyzed by western blotting using the 
appropriate antibodies or the effect of the corresponding knockdown was assayed.  
2.4. Western blot 
 Whole cell lysates were prepared by scraping the cells with laemmli sample 
buffer containing 4% SDS, 20% glycerol, 10% β mecraptoethanol, 0.004% 
bromophenol blue and 0.125M Tris HCL (pH 6.8). SDS-PAGE was carried out 
under standard conditions and proteins were blotted onto a PVDF membrane. The 
membranes were then blocked with 5% non-fat milk 1 hour and then incubated 
overnight at 4°C with either primary antibody against RhoG (abcam, 1:1000 
dilution), or against actin (abcam, 1:2500). After washing and 1 hour incubation with 
the secondary antibodies, blots were developed using chemi-luminescent reagent 
ECL detection kit purchased from (GE Healthcare). The levels of protein expression 
were compared using Image j. 
 
2.5. Motility assay  
 Cells were plated on a 35mm petri dish and transfected with si-Luciferase, si-
RhoG and the assay was performed 72 hours after transfection. For motility analysis, 
cells were imaged in DMEM (10% FBS) media, buffered using HEPES and overlaid 
with mineral oil on a 37°C stage. Images were collected every 60 seconds for 2 hours 
using a 20X objective lens on Zeiss Observer Z1 microscope. The speed on cell 
movement was then qualified using ROI tracker plugin in Image j software and plotted 
in graph-pad prism. 
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2.6. Immunostaining  
The cells were plated on cover slips, starved overnight and treated with the 
phorbol ester PMA an hour before starting the experiment with a final concentration of 
150nm/ml or stimulated with EGF for 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 
minutes and 5 minutes, 10 minutes, 15 minutes for Snb-19 and SF268 cells respectively. 
Cells were fixed with 4% paraformaldehyde or using eddy fix (3.7% formaldehyde, 
0.1% glutaraldehyde, and 0.15mg/ml saponin) for 10 minutes, and permeabilized with 
0.5% Triton-X 100 for 10 minutes. To decrease background fluorescence, cells were 
rinsed with 0.1 M glycine then incubated with 0.1 M glycine for 10 minutes. For 
blocking, cells were incubated 4 times with 1% BSA, 1% FBS in PBS for 5 minutes. 
Samples were stained with primary antibodies for 2 hours and with fluorophore-
conjugated secondary antibodies for 2 hours. Fluorescent images were taken using a 63X 
objective lens on Zeiss Observer Z1 microscope.                           
2.7. Pull-down Assay  
Cells were plated on a 100mm petri dish and grown to 80%-90% confluency. 
Cells were transfected with si-Luciferase and si-RhoG. Then pull down assay was 
carried out for RhoA, Rac1 and cdc42 using Rhotekin RBD and PAK1 PBD agarose 
beads respectively according to the protocol provided by the kit’s manual (Cell Biolabs 
Inc., San Diego, CA92126). 
2.8. Adhesion assay 
96-well plates were coated with collagen using Collagen Solution, Type I 
from rat tail(Sigma) overnight at 37 °C then washed with washing buffer (0.1% BSA 
in DMEM). The plates were then blocked with 0.5% BSA in DMEM at 37 °C in a 
CO2 incubator for 1 hour. This was followed by washing the plates and chilling them 
on ice. Meanwhile, the cells were trypsinized and counted to 4x105 cell/ml. 50 μl of 
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cells were added in each well and incubated at 37°C in a CO2 incubator for 30 
minutes. The plates were then shaken and washed 3 times. Cells were then fixed with 
4% paraformaldehyde at room temperature for 10 minutes, washed, and stained with 
crystal violet (5 mg/ml in 2% ethanol) for 10 minutes. Following the staining with 
crystal violet, the plates were washed extensively with water, and left to dry 
completely. Crystal violet was solubilized by incubating the cells with 2% SDS for 
30 minutes. The absorption of the plates was read at 550 nm using a plate reader. 
 
2.9. Invasion assay 
Cells were transfected with either Luciferase or RhoG siRNAs and invasion 
assay was performed 48 hours following treatment period using the collagen-based 
invasion assay (Millipore) according to manufacturer’s instructions. Briefly, 24 hours 
prior to assay, cells were starved with serum free medium. Cells were harvested, 
centrifuged and then re-suspended in quenching medium (without serum). Cells were 
then brought to a concentration of 1x106 cells/ml. In the meantime, inserts were 
prewarmed with 300μl of serum free medium for 30min at room temperature. After 
rehydration, 250μl of media was removed from inserts and 250μl of cell suspension 
was added. Inserts were then placed in a 24-well plate, and 500μl of complete media 
(with 10% serum) was added to the lower wells. Plates were incubated for 24 hours 
at 37°C in a CO2 incubator. Following incubation period, inserts were stained for 20 
minutes at room temperature with 400μl of cell stain provided with the kit. Stain was 
then extracted with extraction buffer (also provided).100ul of extracted stain was 
then transferred to a 96-well plate suitable for colorimetric measurement using a 
plate reader. Optical Density was then measured at 560μm. 
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2.10. Statistical analysis 
 All the results reported represent average values from three independent 
experiments. All error estimates are given as SEM. The p-values were calculated by 
t-tests or one way analysis of variance (ANOVA) tests depending on the experiment 
using graph pad prism.  
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Chapter 3 
Results 
 
3.1. RhoG knockdown decreases cell migration 
We first checked the level of RhoG protein expression using five siRhoG 
oligos to choose the best two oligos so that we can use them to proceed with our 
experiments. Western bot results show knockdown in oligo 5 and oligo 8. These are 
the 2 oligos that we are going to use throughout our knockdown experiments. By 
doing time-lapse microscopy and using ImageJ to quantitate cell movement, results 
showed that RhoG knockdown decreases cell motility by 20%. These results are not 
significant which shows that cell motility depends on factors and proteins other than 
RhoG. 
 
A.  
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B. 
 
Figure 9: RhoG knockdown. Depletion of RhoG after 72 hours transfection with 
RhoG siRNA (A). RhoG positively regulates 2D cell motility. RhoG positively 
regulates 2D cell motility. Knockdown of RhoG decreased cell motility when 
compared to control cells (B). Image j software was used to quantitate cell 
movement. Tracking was done over 120 frames, looking at 11 cells in each time-
lapse movie, and the average distance was reported. Data are the mean -/+ SEM from 
3 different experiments. The results were significant with p<0.001. 
 
 
3.2. RhoG knockdown decreases cell adhesion to collagen 
We wanted to study the role of RhoG in cell adhesion of these glioblastoma 
cells to collagen. Cell adhesion is an important step in the cell motility cycle. After 
formation of the protrusions, these protrusions need to adhere to the extracellular 
matrix. We studied the effect of RhoG knockdown on cell adhesion. The results 
showed a decrease in cell adhesion by 10% in the cells with knock down (oligo 5) 
and 30% in the cells with knockdown (oligo 8) compared to the control cells.  
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Figure 10: RhoG knockdown decreases cellular adhesion to collagen. A. 
Representative micrographs of cells fixed and stained with crystal violet to detect 
adhesion. B. Quanitation of the micrographs. Crystal violet was solubilized and the 
absorption was taken at 550 μm using ELISA. Data is measured in arbitrary units and 
normalized to the control. 
 
 
3.3. Formation of ruffles in brain cancer cells are RhoG independent 
In order to study the role of RhoG in the formation of ruffles, we must first 
induce the formation of ruffles in brain cancer cells. Ruffles are densely packed actin 
filaments that form at the leading edge of lamellipodia. SNB cells were starved 
overnight and treated with PMA for one hour. Rhodamine phalloidin was then used 
to stain for actin. PMA is a tumor promoter that activates PKC pathway. To test the 
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effect of RhoG on the formation of ruffles, RhoG was knocked down using siRhoG. The 
cells are also starved overnight and stimulated with PMA for one hour. Then Rhodamine 
phalloidin was then used to stain for actin. Results showed that the ruffles formation are 
RhoG independent. This is due to the decrease in cell adhesion in RhoG depleted cells so 
the cells can no more adhere to the extracellular matrix thus they are going to form 
ruffles. 
 
Figure 11: Ruffles formation is RhoG independent. The ruffle structures were still 
present when the cells were transfected with siRhoG also followed by actin staining 
via Rhodamine phalloidin. 
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3.4. RhoG knockdown promotes actin stress fiber formation 
To examine the phenotypic nature of cells upon RhoG knock down, we did 
immunostaining with Rhodamin Phalloidin for control and RhoG depleted cells to 
check for actin stress fibers. Results show that the knock down of RhoG causes the 
formation on actin stress fibers. Actin stress fibers are formed at the rear end of the 
cell. Once they are formed the cell can no longer moves in 2D.  
 
 
Figure 12: Role of RhoG in actin stress fiber formation. Cells were either 
transfected with the control luciferase or with RhoG siRNA. After 72 hours, cell 
were fixed and immunostained using Rhodamin phalloidin to stain actin fibers. 
Micrographs were imaged using 60X objective.  
  
 
 
3.5. Effect of RhoG knockdown on Rho GTPases  
We carried out a pull down assay for RhoA, Rac, and Cdc42 on Snb-19 cell line 
that was treated with siRhoG. Results showed that activated Rac1 and RhoA levels 
increased when RhoG is knocked down as compared to the total Rac levels and the total 
RhoA levels, respectively. However, the activated Cdc42 levels did not change when 
RhoG was knocked down as compared to the total Cdc42 levels. This explains our 
previous results that inhibiting RhoG causes the formation of stress fibers which is 
due to an increase in the activation levels of RhoA. 
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Figure 13: RhoG effect on activated RhoA, Cdc42, and Rac levels. The 
quantitation of western blot shows an increase in the activity of RhoA and Rac1 (A 
and C) for cells transfected with siRhoG compared to the control and a decrease in 
the activity of Cdc42 for cells transfected with siRhoG compared to the control (B). 
 
3.6. RhoG knock down decreases cellular invasion 
After studying the role of RhoG in 2D cell motility, now we wanted to check 
its role in cell invasion. First RhoG was knocked down then the cells were starved 
and plated in boyden chamber. The cells will invade toward media rich in growth 
factors. The invading cells are stained, extracted, and absorbance measured at 560 
nm. Results show that RhoG knockdown decreases cell invasion by 50% in cells 
knocked down with siRhoG oligo 8. 
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Figure 14: RhoG positively regulates 3D cell motility. Knockdown of RhoG 
decreased cell invasion as compared to control cells. Data are the mean -/+ SEM 
from 3 different experiments. The results were significant with p<0.001. 
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Chapter 4 
Discussion 
 
The Rho family is involved in regulating the cytoskeleton. Oncogenic activity 
was shown when the Rho family of proteins was over-expressed (Dasari et al., 2016). 
Previous studies showed that RhoG regulates cell migration and microtubule 
formation (Dasari et al., 2016). In fact, RhoG is considered as a novel target for 
cancer. Therefore, our aim in these experiments was to study the role of RhoG in 
migration and invasion of glioblastoma cells. 
Previous studies showed that RhoG knock down reduced cell migration in 
HeLa cells (Katoh et al., 2006). Therefore, we studied the role of RhoG in 2D and 
3D cell motility. Our findings demonstrated that knocking down RhoG decreases cell 
migration which is consistent with previous results. Thus RhoG is needed for 
migration of cancer cells which is an important feature for metastasis.  
An adhesion assay was performed to study the role of RhoG in the formation 
of focal adhesions. Focal adhesions are sites that link to the actin filaments (Wozniak 
et al., 2004). The formation of focal adhesions is regulated by GTPases and kinases 
(Wozniak et al., 2004). Therefore, we were interested in looking at the cellular 
adhesions after knocking down RhoG. Our results showed that upon knocking down 
RhoG, cellular adhesion decreases. Thus, RhoG plays a role in adhering to the ECM. 
Previous work in our lab (Saleh Al Dimassi’s thesis) showed that knocking down 
RhoC causes an increase in astrocytoma cell adhesion. This could relieve an 
antagonistic relationship between RhoG and RhoC. 
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 Since protrusion plays a role in cell motility, it was important to study the 
effect of RhoG on protrusion and ruffle formation. Ruffles are densely packed actin 
filaments which arise at the leading edge of lamellipodia (Borm et al., 2005). 
Previous studies showed that the formation of ruffles indicates inefficient migration 
(Borm et al., 2005). First, we wanted to induce the formation of ruffles by starving 
the cells overnight and stimulating with PMA for one hour. Our results showed that 
the formation of ruffles was not affected when RhoG was knocked down. Therefore, 
ruffles formation are RhoG independent. However the formation and composition of 
these ruffles remained unknown. The formation of membrane ruffling in RhoG 
depleted glioblastoma cells is due to the decrease in cell adhesion.  
Our next aim was to look at the role of RhoG in stress fiber formation. It is 
previously known in the literature that RhoA is active at the rear end of the cell and 
thus forming stress fibers (Goldberg & Kloog, 2006). The stress fibers are formed by 
the activity of ROCK which is downstream effector of RhoA (Maekawa et al., 1999). 
Previous work done in our lab showed that upon knocking down StarD13 (Anita 
Nasrallah’s thesis), RhoA is highly active and hence forming stress fibers and 
stabilizing focal adhesions. Once the stress fibers are formed the cell is stuck and can 
no longer move in 2D. Thus the formation of stress fibers indicates inefficient 
migration (Borm et al., 2005). When we knocked down RhoG our results showed 
that the cells will form stress fibers. This implies a relationship between RhoA and 
RhoG that will be elucidated later in the pull down assay.   
 
The next step was to study the effect of RhoG on 3D cell motility as in cell 
invasion. Previous results showed that depletion of RhoG strongly inhibits 
glioblastoma invasion (Kwiatkowska et al., 2012). Our data showed that knocking 
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down RhoG also decreases cell invasion in glioblastoma which is consistent with 
previous studies. Several previous experiments showed a relation between invasion 
of glioblastoma cells and their survival potential (Mariani et al., 2001). This suggests 
the presence of signaling nodes that link cell invasion with survival of the tumor 
(Hoelzinger et al., 2005). Therefore, these signaling nodes play important role as 
therapeutic targets for tumors. Previous experiments done in our lab showed that 
RhoA decreases astrocytoma cell invasion which suggests that knocking down RhoG 
increases RhoA and thus decreases cell invasion. 
We wanted to study the signaling relationship between RhoG, RhoA, Cdc42, 
and Rac1. Pull down assay is done to study the activation levels of Rho GTPases. 
RBD beads bind Rho whereas PAK1 PBD (p21 activating kinase p21 GTPase 
binding domain) bind Rac and Cdc42. RhoG knock down was done followed by a 
pull down assay to monitor the activation levels of RhoA, Cdc42, and Rac1. The 
activation levels of Cdc42 did not change when RhoG was knocked down. However 
the activation levels of RhoA and Rac1 were shown to increase after RhoG 
knockdown. Thus, RhoG downregulates RhoA and Rac1 activation levels. This 
explains our previous results that inhibiting RhoG causes the formation of stress 
fibers which is due to the activation levels of RhoA. RhoA will act at the rear end 
and causes the formation of these stress fibers. On the other hand, previous 
experiments showed that depleting glioblastoma cells from Rac1 led to inhibition of 
lamellipodia. This shows that Rac1 plays a role in the formation of lamellipodia. 
Thus we can conclude that inhibiting RhoG will lead to the formation of lamellipodia 
at the leading edge. 
So far, we have shown that RhoG is needed in cell motility like other Rho 
GTPases. However RhoG doesn’t play a role in the formation of ruffles which is 
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consistent with previous studies that showed that only RhoA, Cdc42, and Rac1 play a 
role in the formation of ruffles (Borm et al., 2005). We also showed that RhoG is 
important in cell movement since its absence forms stress fibers.  
Moreover, we showed that RhoG mediates glioblastoma cell invasion. Also 
RhoG plays important role in cell adhesion.  
Additionally, RhoG interacts with other Rho GTPases. RhoG downregulates 
RhoA and Rac1 activation levels. However no effect was found on Cdc42. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 39 
 
Chapter 5 
Conclusion  
In this study, we looked at the role of RhoG in the migration and invasion of 
glioblastoma cells. Our results suggest that RhoG is important in cell motility, 
invasion, and adhesion. Moreover RhoG was shown to downregulates Rac1 and 
RhoA. In addition, knocking down RhoG was shown to decrease cell adhesion to 
collagen so future work will look at the adhesion structures to study the relation 
between RhoG and cell adhesion. RhoG contributes significantly to the malignant 
behavior of glioblastoma cells. Therefore, RhoG can be used as a sign of cancer 
metastasis and hence it can be used as a therapeutic target for cancer.  
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